#United States #New York #Blood Cancer United #Royalty Pharma #Therapy Acceleration

Blood Cancer United Secures Major Funding for Therapy Acceleration Program

In a significant development for blood cancer therapies, Blood Cancer United has announced a generous donation of $7.5 million from Royalty Pharma. This funding is part of an initiative aimed at accelerating the development of promising blood cancer treatments through the Therapy Acceleration Program (TAP). TAP represents a collaborative venture philanthropy approach designed to forge new partnerships and push forward therapies that urgently need development.

A New Era for Therapy Acceleration Program

The recent donation from Royalty Pharma marks a crucial moment for TAP, which now stands as the first and largest corporate contribution under a restructured model that enables direct donations. This model is expected to enhance the program's capability to nurture early-stage biotech companies aiming to develop therapies for unmet medical needs in blood cancers.

The funding will not only provide vital financial resources, but TAP also commits to offering substantial scientific, clinical, and business guidance. This initiative is crucial in connecting companies working on new therapies with a global network of blood cancer experts, ultimately facilitating a faster path to patient access to these innovative treatments.

Dr. E. Anders Kolb, the president and CEO of Blood Cancer United, emphasizes the urgency of this initiative. He states, “As scientific advancements open new doors for patients, we still see many potential therapies fail to reach those who need them the most. TAP is pivotal in pushing these therapies forward during critical developmental phases where resources and expertise can make all the difference.”

Empowering the Future of Blood Cancer Treatment

With the TAP model, Blood Cancer United envisions a system where positive clinical outcomes lead to essential regulatory approvals, thus generating new treatment opportunities for patients. Crucially, any financial returns received from these investments will be reinvested back into TAP, allowing for an ongoing cycle of funding that will continuously support future partnerships and investments.

Royalty Pharma’s involvement builds upon a collaborative history with Blood Cancer United. In 2022, the two organizations initiated a five-year, $7.5 million alliance aimed at tackling healthcare disparities in blood cancer treatment, particularly by increasing access to clinical trials for marginalized communities. This latest donation is a continuation of that mutual commitment to clinical development and patient support.

Pablo Legorreta, the CEO and Chairman of Royalty Pharma, shares his excitement about this partnership, stating, “For close to three decades, Royalty Pharma has been at the forefront of investing in scientific and medical advancements. We believe that innovations can only change patients' lives when successfully converted into real medicines. Our latest donation underscores our commitment to fostering blood cancer innovation and our confidence in Blood Cancer United’s capacity to deliver results.”

A Proven Record of Advancing Therapy Development

Launched in 2007, TAP has played an essential role in expediting blood cancer therapies into the clinical development phase. Since its inception, the program has successfully supported the progress of six significant therapies that have gained approval from the U.S. Food and Drug Administration (FDA) or have been integrated into the National Comprehensive Cancer Network guidelines. Currently, more than 30 active clinical studies involving TAP-supported therapies are underway.

Industry leaders, like Troy Wilson, Ph.D., JD, president, CEO, and co-founder of Kura Oncology, view TAP and Royalty Pharma as a strategic pairing that combines perseverance, intelligence, and investment power essential for the development of new treatments, particularly for rare diseases. Wilson notes, “This partnership emphasizes our shared belief that patients must always be at the center of every decision we make.”

Looking Ahead

As they near the 20-year mark, the Therapy Acceleration Program continues to solidify its position as a leader in accelerating blood cancer health advancements. With Royalty Pharma’s donation now fueling the next chapter for TAP, Blood Cancer United is poised to make substantial strides in delivering new treatment options to patients. By enhancing funding, expert resources, and fostering collaborations, TAP will aim to revolutionize how therapies addressing significant unmet needs in blood cancer are developed.

Through sustained efforts and new strategies, Blood Cancer United and its partners feel optimistic about the future of cancer treatment, hoping to change lives one therapy at a time.